The Board of Directors is made up of members who bring a variety of skills, talents and backgrounds particularly well suited for Cancer Research And Biostatistics. Included are oncologists and biostatisticians with clinical trials and cancer prevention backgrounds, financial experts, and scientists with entrepreneurial and federally backed experience. The Board takes its fiduciary responsibilities to heart: it approves the selection of the financial auditors; and approves the annual budget, the annual audit, tax reports and regularly published financial statement. Beyond its fiduciary role, the Board is primarily advisory in nature. Each member sits on at least one subcommittee: development, renewal, finance and professional conduct. Board members are seated for three-year, renewable terms.
To see biographical information please click on a name below.
Cynthia Adkins, J.D.
Adkins, Plant, Elvins & Black, PLLC
Cynthia Adkins brings over twenty-two years of legal experience to the CRAB Board of Directors.
As a founder and managing member of Adkins, Plant, Elvins & Black, a life sciences law firm that serves the biotechnology, pharmaceutical and medical device industries, Cynthia Adkins provides legal solutions for the life sciences by focusing primarily on international and domestic clinical trials and research and manufacturing transactions, and negotiating with sites and companies in the United States, Europe, Russia, Asia and South America. Ms. Adkins travels extensively to support her clients’ international requirements, and she has established a strong network of international life sciences counsel to assist with local law issues.
Before co-founding her own firm, she served as senior counsel for Immunex Corporation, where she negotiated biotechnology manufacturing agreements, clinical trial agreements, supply agreements, software licenses and internet hosting agreements. She was the recipient of the company’s “Applause Award” for her timely divestiture of four oncology products. Throughout her extensive legal career, Cynthia also served as senior counsel at Home Grocer.com, counsel and Vice-President at Washington Mutual Bank, and counsel to the treasury group at Boeing.
Cynthia holds a BA from Washington State University and a Juris Doctorate from the University of Washington.
Michael LeBlanc, Ph.D.
SWOG Group Statistician
Dr. LeBlanc is a full member of the Fred Hutchinson Cancer Research Center, a Research Professor of Biostatistics at the University of Washington and both the current Group Statistician and Principal Investigator of the SWOG Statistical Center Grant (Cooperative Agreement Award No. 5 U10 CA038926-27). He brings extensive experience in the design and analysis of clinical trials and also a significant personal research record both in clinical trials and adaptive regression methods relevant to the analysis of clinical trials and cohort data.
Dr. LeBlanc’s collaborative research focuses on statistical activities related to Phase II and Phase III clinical trials. His research interests include the design and analysis of clinical trials, methods for exploratory analysis of survival data and adaptive non-parametric regression. Most of his collaborative research focuses on the design, analysis and conduct of therapeutic clinical trials. Dr. LeBlanc holds a Ph.D. from the University of Washington and a Masters in Mathematics from the University of Waterloo.
M. Patricia Beckmann, Ph.D.
Chief Technology Development Officer
CVI (CDRD Ventures, Inc.)
Dr. Patricia Beckmann’s career spans research, operations, law and venture capital. Patricia spent most of her career at Immunex Corporation (and Amgen) in Research, Administration and Law where she co-invented the blockbuster drug Enbrel and was awarded National Inventor of the Year in 2000. She was an Investment Specialist at Vulcan Capital deploying nearly $40M in various investments and a member of the original strategy team establishing the $100M endowed Allen Institute for Brain Sciences. Dr. Beckmann was also President of the Oregon Translational Research and Development Institute where she developed an incubator model for bioscience start-ups. More recently she has taken on the role of Chief Technology Development Officer at CVI Ventures (the commercial arm of the Centre for Drug Research and Development in Vancouver, Canada).
Patricia serves on the Boards of CRAB, Jasmin Pharmaceuticals, the Drug and Device Advisory Council of the Institute for Translational and Health Sciences at UW, and the Advisory Board of Northwest Technology Ventures. She earned her PhD in biochemistry and pharmacology from the University of Arizona, College of Medicine, is a two-time Fulbright Scholar (Sweden and India), an NRSA Fellow at the National Cancer Institute and a Kauffman Fellow. She has over 50 peer-reviewed scientific publications and over 40 issued U.S. Patents to her credit.
Glenn Chinn, M.A.
Glenn Chinn applies his financial skills and entrepreneurial background to nonprofit and community development endeavors. He has a keen understanding of finances and administrative infrastructures and provides seasoned executive leadership especially to startup projects. Mr. Chinn is able to mobilize and maximize resources of ethnically diverse work forces. His professional experience includes having him manage finances and administration for international development, housing resource, community and neighborhood, and service projects. Mr. Chinn received his B.A. from Claremont McKenna College and M.A. from University of Washington.
John Crowley, Ph.D.
Chief of Strategic Alliances
Cancer Research And Biostatistics (CRAB)
Since founding CRAB in 1997, Dr. Crowley has served as a sitting member of, and has chaired, the Board of Directors. Dr. Crowley oversees all science conducted at CRAB as well as all research procedures and operations. John was conferred an M.S. and Ph.D. in Biomathematics from University of Washington and has devoted his career to applying statistics to cancer research. Please see more information in his biography.
Frank X. Curci, J.D.
Ater Wynne, LLP
Frank X. Curci is an intellectual property and technology attorney and a partner at Ater Wynne LLP. Frank represents clients regarding their intellectual property, research and technology matters, including patent/technology licensing, technology collaborations, research issues, technology transfers, and the overall development, protection, commercialization, and use of intellectual property rights. Mr. Curci’s clients include bioscience and high-technology companies, research universities, other bioscience research institutions, and technology accelerator entities. Frank is active with bioscience and high tech industry associations, including the Oregon Bioscience Association and, previously, the Arizona BioIndustry Association. For several years he has been an Adjunct Professor of Law teaching intellectual property law courses at Oregon, California and Arizona law schools and currently teaches at Lewis & Clark Law School in Portland, OR.
Susan Finneran, M.B.A.
Commerce Bank of Washington
Susan has been providing banking services to locally owned businesses and their officers since 1977 and at The Commerce Bank of Washington since 1988. She has earned accolades for her work with both middle-market and large national companies. Currently, Ms. Finneran serves on the nonprofit Boards of Cancer Research And Biostatistics and the Market Foundation. Previously she was on the Boards of Camp Fire USA (local and national), United Way of King County, Seattle Architectural Foundation and Cancer Lifeline. Ms. Finneran graduated from the University of Colorado with a B.S. in Business and has completed graduate studies in Business at N.Y.U. and Seattle University.
“The greatest satisfaction I get as a banker comes from truly getting to know my client’s business, and then creatively participating in their financial planning and structuring.” - Susan Finneran
Gary Goodman, M.D., M.S.
Swedish Hospital Tumor Institute
The interests of Dr. Goodman dovetail uniquely with those of CRAB. He is an oncologist at Swedish Hospital in Seattle and also holds a joint membership with the Fred Hutchinson Cancer Research Center. He has held prominent positions in SWOG, the most pertinent to CRAB is his Chairmanship of the Chemoprevention Committee. He was the Principal Investigator (PI) of the Carotene and Retinol Efficacy Trial (CARET) and Principal Investigator at Swedish for SWOG’s Selenium and Vitamin E Cancer Prevention Trial (SELECT). Dr. Goodman has been an advisor to the SWOG H Pylori Project in South and Central America. The latter two, massive projects have both been coordinated by the Statistical Center of SWOG at CRAB. Dr. Goodman has been a long-time supporter of CRAB, serving on its IRB for 10 years. Dr. Goodman received his M.D. and M.S. in Pharmacology from the University of Illinois in 1974.
David Gray, Ph.D., M.B.A.
Dr. Gray has over twenty years of clinical drug development experience in the pharmaceutical and biotechnology industries in a variety of positions including overseeing clinical development and statistics. He is currently a senior manager at Seattle Genetics. His current therapeutic focus is oncology product development. Prior therapeutic experience includes infectious, respiratory, and cardiovascular diseases, aerosol drug delivery, and radiopharmaceuticals and he has participated in several successful product registrations and marketing authorizations. Dr. Gray has a Ph.D. in statistics from the University of Kentucky and an M.B.A. from the University of Pennsylvania.
Senior Financial Advisor
John is a Senior Financial Advisor, working with private wealth clients and also working closely with board members of foundations and other nonprofit organizations. Central to his efforts are risk-focused, tax minimizing portfolios designed to pursue client goals. John previously worked for Fidelity Investments, in Boston, and with Morgan Stanley. He earned his bachelor’s degree in communication at the University of Colorado. He has lived in Seattle since 2004, and for the past three years has served on the board for Band of Brothers, NW, a nonprofit that helps families of terminally ill children. Additionally, in John’s free time, he enjoys playing golf, skiing and riding motorcycles as well as spending time with his wife Hillary and their 8 year old boxer Cassius.
Antje Hoering, Ph.D.
Chief Executive Officer
Cancer Research And Biostatistics
Antje Hoering, Ph.D is President and CEO at Cancer Research And Biostatistics (CRAB). Dr. Hoering brings distinguished academic and scientific achievements, executive leadership and over 15 years of experience to the role. She presently serves as the lead statistician for the SWOG Myeloma Committee and is an active member of the Myeloma Steering Committee for the National Clinical Trials Network. Dr. Hoering also serves as the Director of the Biostatistics Core for a SPORE grant funded through the Sarcoma Alliance for Research Through Collaboration, and is the Co-Director of the Biostatistics Core for a Program Project through the Myeloma Institute. Dr. Hoering also serves as a consultant on a variety of industry sponsored studies, including a phase III registration trial and has been the biostatistics representative on two Type B meetings with the FDA. Dr. Hoering holds affiliate appointments at the Fred Hutchinson Cancer Research Center and the Biostatistics Department of the University of Washington.
Dr. Hoering has a unique and comprehensive background in applied and methodological research in biostatistics, encompassing areas such as the design and analysis of oncology clinical trials as well as the analysis of a wide variety of correlative data. Dr. Hoering joined CRAB in 2004 as a Senior Biostatistician. In 2013 she was promoted to Chief Scientific Officer to lead the CRAB statistics team before being promoted to President and CEO in 2015.
Before joining CRAB, Dr. Hoering was a senior research associate at the Cancer Center at the Mayo Clinic, and an Assistant Professor at the Mayo Medical School, Rochester, Minnesota. While at the Mayo Clinic she was the lead statistician on several Phase I, II, and III clinical trials in hematological malignancies and breast cancer. She managed a team of statisticians and data analysts in the design, conduct and analysis of these clinical trials.
Dr. Hoering's original training was in physics. She obtained her BS at the University of Tuebingen, Germany, an MS from Oregon State University, and a PhD from the Max-Planck-Institute for Nuclear Physics in Heidelberg, Germany. She transitioned into biostatistics as an NIH post-doctoral fellow at the Biostatistics Department of the University of Washington. During that time she completed the coursework required for a PhD in Biostatistics, and also performed methods research in the area of HIV vaccine trials at the Fred Hutchinson Cancer Research Center.
Curt Malloy, J.D., M.P.H.
Administrator, Vaccine and Infectious Disease Division
Fred Hutchinson Cancer Research Center
Curt Malloy is the operational leader for the Fred Hutchinson Cancer Research Center’s Vaccine and Infectious Disease Division. Curt is a strong advocate for life sciences and product development playing a role in strategies to reduce the global burden of disease.
Curt has long-standing professional experience in the fields of epidemiology, global health, and intellectual property law. Curt's education includes a bachelor’s degree in Chemistry and Computer Science from Pacific Lutheran University; a Masters in Public Health from Columbia University; and a Juris Doctor, with an emphasis in Intellectual Property, from the Seattle University School of Law.
Curt is an adjunct professor at the Seattle University School of Law, as well as in the Seattle University Institute for Public Service, where he teaches a course in global health to students in the Masters of Public Administration program. He is fluent in Spanish.